How big is Veru, Inc.?

As of Jun 18, Veru, Inc. has a market capitalization of 86.33 million, with net sales of 10.61 million and a net profit of -29.16 million over the last four quarters. The company reported shareholder's funds of 32.32 million and total assets of 60.81 million as of Sep 24.

Market Cap: As of Jun 18, Veru, Inc. has a market capitalization of 86.33 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Veru, Inc. reported net sales of 10.61 million and a net profit of -29.16 million.<BR><BR>Balance Sheet Snapshot: As of Sep 24, the company reported shareholder's funds of 32.32 million and total assets of 60.81 million.

What does Veru, Inc. do?

Veru, Inc. is a biopharmaceutical company focused on developing treatments for prostate cancer, with a market cap of USD 86.33 million and a recent net profit of -8 million. The company operates in the Pharmaceuticals & Biotechnology industry and has no dividend yield.

Overview: <BR>Veru, Inc. is an oncology and urology biopharmaceutical company focused on developing medicines for the management of prostate cancer, operating in the Pharmaceuticals & Biotechnology industry with a market cap of USD 86.33 Million.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -8 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 86.33 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.92 <BR>Return on Equity: -178.53% <BR>Price to Book: 4.10<BR><BR>Contact Details: <BR>Address: 48 NW 25th St Ste 102, MIAMI FL: 33127-4442 <BR>Tel: 1 312 5959123 <BR>Fax: 1 312 5959122 <BR>Website: https://verupharma.com/

Should I buy, sell or hold Veru, Inc.?

Who are in the management team of Veru, Inc.?

As of March 2022, the management team of Veru, Inc. includes Dr. Mitchell Steiner as Chairman, President, and CEO, and Dr. Harry Fisch as Vice Chairman and Chief Corporate Officer, along with independent directors Dr. Mario Eisenberger, Mr. Michael Rankowitz, and Mr. Jesus Socorro.

As of March 2022, the management team of Veru, Inc. includes Dr. Mitchell Steiner, who serves as the Chairman of the Board, President, and Chief Executive Officer. Dr. Harry Fisch holds the position of Vice Chairman of the Board and Chief Corporate Officer. Additionally, the board features independent directors Dr. Mario Eisenberger, Mr. Michael Rankowitz, and Mr. Jesus Socorro.

Is Veru, Inc. overvalued or undervalued?

As of February 9, 2022, Veru, Inc. is considered overvalued and has a risky valuation grade due to poor financial metrics and significant underperformance compared to the S&P 500, with a year-to-date return of -45.12% and a 3-year return of -97.50%.

As of 9 February 2022, the valuation grade for Veru, Inc. has moved from fair to risky, indicating a significant deterioration in its financial outlook. The company appears to be overvalued given its substantial negative performance metrics, including a Price to Book Value of 4.37, an EV to EBIT of -1.84, and an EV to EBITDA of -1.85. Comparatively, peers like G1 Therapeutics, Inc. and ADC Therapeutics SA show even worse EV to EBITDA ratios of -9.6487 and -4.7475, respectively, but Veru's metrics still suggest a concerning valuation.<BR><BR>The stock has underperformed significantly against the S&P 500, with a year-to-date return of -45.12% compared to the index's 12.22%. This trend continues over longer periods, with a 3-year return of -97.50% versus the S&P's 70.41%. Overall, the combination of poor financial ratios and substantial negative returns indicates that Veru, Inc. is overvalued in the current market context.

Is Veru, Inc. technically bullish or bearish?

As of September 8, 2025, Veru, Inc. shows a mildly bullish trend despite bearish indicators in the weekly MACD and moving averages, with a year-to-date return of -45.12% compared to the S&P 500's 12.22%.

As of 8 September 2025, the technical trend for Veru, Inc. has changed from bullish to mildly bullish. The weekly MACD is bearish, while the monthly MACD is mildly bullish. The weekly RSI indicates bullish momentum, but the monthly RSI shows no signal. Bollinger Bands are mildly bearish on both weekly and monthly time frames. Daily moving averages are bearish, and both KST and Dow Theory show no trend on the weekly and monthly charts. <BR><BR>In terms of performance, Veru has underperformed the S&P 500 across multiple periods, with a year-to-date return of -45.12% compared to the S&P 500's 12.22%, and a one-year return of -53.64% versus the S&P 500's 17.14%. Overall, the current stance is mildly bullish, but the strength is tempered by bearish indicators in the weekly MACD and moving averages.